Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A modification of MEKK1 promote the progression of PDAC
Theranostics · 2025
DOI: 10.7150/thno.117202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2025. Verfasst von Shengnan Lv und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China, 130021. Hauptthemen laut MEDLINE: RNA, Circular, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, RNA-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China, 130021.
- Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Jilin, China, 130117.
Zitieren
APA
Lv, S., Zhang, J., Peng, X., Liu, H., Chu, T., Liu, Z., Duan, K., Guo, J., Wang, J., Liu, Y., & Wei, F. (2025). Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A modification of MEKK1 promote the progression of PDAC. Theranostics. https://doi.org/10.7150/thno.117202
Vancouver
Lv S, Zhang J, Peng X, Liu H, Chu T, Liu Z, et al. Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A modification of MEKK1 promote the progression of PDAC. Theranostics. 2025. doi:10.7150/thno.117202
BibTeX
@article{Lv2025,
author = {Lv, Shengnan and Zhang, Jian and Peng, Xinyu and Liu, Huan and Chu, Tongjia and Liu, Ziyu and Duan, Kehang and Guo, Jianxiong and Wang, Jie and Liu, Yan and Wei, Feng},
title = {Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A modification of MEKK1 promote the progression of PDAC},
journal = {Theranostics},
year = {2025},
doi = {10.7150/thno.117202}
}
EUVIMED